Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track EXEL with free AI briefings, catalyst countdowns, and dilution alerts.

EXEL · EXELIXIS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.5B Cash on Hand
CF+ Cash Runway
Follow EXEL by email Get an email when EXEL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about EXEL, unsubscribe in one click. Privacy

📣 What EXEL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Cabozantinib
FDA approved Nov 2012 · Cometriq
Medullary Thyroid Cancer Phase 4 · NCT01896479 Active not recruiting
Zanzalintinib (XL092) Pancreatic Neuroendocrine Tumor (pNET) Phase 2/3 · NCT06943755 Recruiting
Sunitinib Renal Cell Carcinoma Phase 3 · NCT03141177 Completed
Berahyaluronidase Alfa and Pembrolizumab Colorectal Cancer Phase 3 · NCT07750158 Recruiting
Tegavivint Hepatocellular Carcinoma (HCC) Phase 1/2 · NCT07878689 Not yet recruiting
Regorafinib Cancer Phase 2 · NCT03899155 Recruiting
Nab-paclitaxel Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 2 · NCT07845786 Recruiting
USP1 Inhibitor ISM3091 Advanced Solid Tumor Phase 1 · NCT05932862 Active not recruiting
Anti-5T4/MMAE Antibody-drug Conjugate XB010 Locally Advanced or Metastatic Solid Tumors Phase 1 · NCT06545331 Recruiting
DDI Probe Cocktail Renal Cell Carcinoma (RCC) Phase 1 · NCT05176483 Recruiting

Also used in these trials (approved or third-party drugs, not EXEL's own candidates): Abiraterone Acetate, Sunitinib Malate, Prednisone, Nivolumab, Ipilimumab, Everolimus, Enzalutamide, Atezolizumab, Belzutifan, Abemaciclib, Tremelimumab, Trametinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

EXEL holds $1.5B in cash and short-term investments (as of Oct 2, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EXEL files for a raise →

👥 Who Owns EXEL

Insiders 3% Other 5%+ holders 6.4% Institutions (1021 holders) 90.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
Dapice Joshua J. 5%+ holder (13D) 15,709,500 6.44% 2026-01-01
Farallon Capital Management, L.L.C. Institution (13G, 5%+) 14,694,910 6.02% 2026-11-09
Vanguard Capital Management Institution (13G, 5%+) 13,233,247 5.42% 2026-03-31
Michael Morrissey
President and CEO, Director
Insider 3,384,063 1.39% 2026-05-15
Stelios Papadopoulos
Director
Insider 1,197,595 0.49% 2026-05-27
Christopher J. Senner
EVP and CFO
Insider 955,040 0.39% 2026-05-15
Dana Aftab
EVP, Research and Development
Insider 600,576 0.25% 2026-05-26
Patrick J. Haley
EVP, Commercial
Insider 357,638 0.15% 2026-05-20
Jack L Wyszomierski
Director
Insider 284,384 0.12% 2026-06-01
George Poste
Director
Insider 127,199 0.05% 2026-05-27
Brenda Hefti
SVP and General Counsel
Insider 112,289 0.05% 2026-05-15
Maria C Freire
Director
Insider 109,186 0.04% 2026-05-27

Share count 244,010,895 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full EXEL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EXEL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.